Brief: Island Pharmaceuticals Announces Purchase Of Galidesivir Antiviral Program From Biocryst Pharmaceuticals
09/07/2025 02:33
July 9 (Reuters) - Island Pharmaceuticals Ltd ILA.AX: ACQUISITION OF GALIDESIVIR ANTIVIRAL PROGRAM FROM BIOCRYST PHARMACEUTICALS DEAL COMPLETED FOR BASE PURCHASE PRICE OF $550,000 Further company coverage: ILA.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Island Pharmaceuticals
See all newsBrief: Island Pharmaceuticals Says Pivotal Marburg Data Secured For Galidesivir FDA Pathway
Brief: Island Pharmaceuticals Posts Prelim FY Loss Attributable Of A$9.8 Million
Australia's Island Pharmaceuticals rises as company boosts Galidesivir production
Brief: Island Pharmaceuticals Boosts Galidesivir Supply As Ebola Surges
Island Pharmaceuticals hits seven-month high on Galidesivir approval for Ebola epidemic